SuperTrans Medical Company
"Novel Antibiotics for Targeting Resistant Bacteria."
SuperTrans Medical (STM) is a preclinical stage biopharmaceutical company developing novel antibiotics that target resistant bacteria.
STM develops novel antibiotics through the use of its guanidinium-rich molecular transporter (GR-MoTr) technology. Conjugation of the GR-MoTr technology to existing FDA-approved antibiotics results in superior antimicrobial properties. These features are evidenced by significantly improved capabilities in eradicating biofilms and multidrug-resistant pathogens, including gram-negative bacteria.
The antibiotic-GR-MoTr conjugate permits improved docking of the molecule to the outer bacterial membrane, enabling effective breaching and delivery of cargo to target sites within the bacteria. STM has already identified a number of candidates worthy of late-stage development that target gram-positive and gram-negative pathogens, including third-generation cephalosporin and carbapenem-resistant strains.
SuperTrans Medical holds an exclusive worldwide license for the GR-MoTr technology, which was discovered by Professor Paul A. Wender and Professor Lynette Cegelski.
Combating Coronavirus Pandemic:
SuperTrans Medical's solution helps address the Coronavirus Pandemic.
SuperTrans Medical (STM) is a preclinical stage biopharmaceutical company developing novel antibiotics that target resistant bacteria.
STM develops novel antibiotics through the use of its guanidinium-rich molecular transporter (GR-MoTr) technology. Conjugation of the GR-MoTr technology to existing FDA-approved antibiotics results in superior antimicrobial properties. These features are evidenced by significantly improved capabilities in eradicating biofilms and multidrug-resistant pathogens, including gram-negative bacteria.
The antibiotic-GR-MoTr conjugate permits improved docking of the molecule to the outer bacterial membrane, enabling effective breaching and delivery of cargo to target sites within the bacteria. STM has already identified a number of candidates worthy of late-stage development that target gram-positive and gram-negative pathogens, including third-generation cephalosporin and carbapenem-resistant strains.
SuperTrans Medical holds an exclusive worldwide license for the GR-MoTr technology, which was discovered by Professor Paul A. Wender and Professor Lynette Cegelski.
Combating Coronavirus Pandemic:
SuperTrans Medical's solution helps address the Coronavirus Pandemic.
Technology:
COVID Treatments
Industry:
Vaccine Development
Headquarters:
Israel
Founded Date:
2019
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership